|
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Imatinib Mesylate in Treating Patients With Salivary Gland Cancer conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Clinical research trials and Imatinib Mesylate in Treating Patients With Salivary Gland Cancer health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Imatinib Mesylate in Treating Patients With Salivary Gland Cancer. Imatinib Mesylate in Treating Patients With Salivary Gland Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Imatinib Mesylate in Treating Patients With Salivary Gland Cancer clinical trial. Human subjects frequently get the finest healthcare available for their Imatinib Mesylate in Treating Patients With Salivary Gland Cancer condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > Imatinib Mesylate in Treating Patients With Salivary Gland Cancer  Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
For Condition: stage 3 salivary gland cancer,recurrent salivary gland cancer,salivary gland adenoid cystic carcinoma,stage 4 salivary gland cancer
Status: No longer recruiting
Sponsor(s): Princess Margaret Hospital , National Cancer Institute (NCI)
Synopsis: RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have unresectable and/or metastatic salivary gland cancer.
Details: OBJECTIVES: - Determine the antitumor activity of imatinib mesylate, in terms of objective response rates (partial and complete responses) and duration of overall response, in patients with unresectable and/or metastatic adenoid cystic, lymphoepithelioma-like, or myoepithelial salivary gland cancer. - Determine the safety and tolerability of this drug in these patients. - Correlate the activity of c-kit and downstream kinases in pre- and post-treatment tumoral biopsies with clinical course in patients treated with this drug. - Determine the effect of treatment with this drug on tumor samples from these patients in terms of proliferation, apoptosis, and angiogenesis. - Correlate the steady state levels of this drug achieved with clinical and laboratory correlative endpoints in these patients. - Determine whether early changes in metabolic activity correlate with molecular changes and predict outcome to therapy in these patients. OUTLINE: This is a multicenter study. Patients receive oral imatinib mesylate twice daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with stable disease receive treatment for up to 6 months. Patients are followed within 3 weeks and then every 3 months thereafter. PROJECTED ACCRUAL: A total of 12-37 patients will be accrued for this study within 6-19 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically or cytologically confirmed adenoid cystic, lymphoepithelioma-like, or myoepithelial salivary gland cancer - Unresectable AND/OR - Radiologically documented metastatic disease - c-kit positive tumor (1+, 2+, or 3+) - At least 1 unidimensionally measurable lesion - More than 20 mm by conventional techniques OR - More than 10 mm by spiral CT scan - No known brain metastases PATIENT CHARACTERISTICS: Age - 18 and over Performance status - ECOG 0-2 Life expectancy - More than 12 weeks Hematopoietic - Absolute neutrophil count greater than 1,500/mm3 - Platelet count greater than 100,000/mm3 Hepatic - Bilirubin less than 1.25 times upper limit of normal (ULN) - AST/ALT less than 2.5 times ULN Renal - Creatinine less than 1.25 times ULN OR - Creatinine clearance greater than 50 mL/min Cardiovascular - No myocardial infarction within the past 6 months - No congestive heart failure - No unstable angina - No active cardiomyopathy - No unstable ventricular arrhythmias - No uncontrolled hypertension Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 3 months after study - No other active malignancy within the past 5 years except adequately treated carcinoma in situ of the cervix or non-melanomatous skin cancer - No uncontrolled psychotic disorders - No serious infections - No active peptic ulcer disease - No other serious medical condition that would preclude study - No prior allergy to compounds of similar chemical or biologic composition as imatinib mesylate PRIOR CONCURRENT THERAPY: Biologic therapy - No concurrent filgrastim (G-CSF) Chemotherapy - At least 4 weeks since prior chemotherapy and recovered - No concurrent chemotherapy Endocrine therapy - Not specified Radiotherapy - At least 4 weeks since prior radiotherapy and recovered - No concurrent radiotherapy to sites of measurable disease Surgery - At least 4 weeks since prior surgery and recovered Other - No other concurrent investigational agents - No concurrent therapeutic warfarin - Mini-dose warfarin for prophylaxis or low-molecular weight heparin allowed - No concurrent erythromycin - No concurrent acetaminophen doses exceeding 3 g/day
Total Enrollment:
Location and Contact Information:
Overall Study Official:
GeorgeBrowman, Study Chair, Cancer Care Ontario-Hamilton Regional Cancer Centre
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
United States
Siteman Cancer Center
St. Louis, Missouri, 63110
United States
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61602
United States
Ingalls Memorial Hospital
Harvey, Illinois, 60426
United States
Central Illinois Hematology Oncology Center
Springfield, Illinois, 62701
United States
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
United States
CCOP - Northern Indiana CR Consortium
South Bend, Indiana, 46601
United States
LaGrange Memorial Hospital
LaGrange, Illinois, 60525
United States
Fort Wayne Medical Oncology and Hematology, Incorporated
Ft. Wayne, Indiana, 46885-5099
United States
Lakeland Medical Center - St. Joseph
Saint Joseph, Michigan, 49085
United States
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
United States
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
United States
Evanston Northwestern Health Care - Evanston Hospital
Evanston, Illinois, 60201
United States
Loyola University Medical Center
Maywood, Illinois, 60153
United States
Cancer Care Ontario-Hamilton Regional Cancer Centre
Hamilton, Ontario, L8V 5C2
Canada
Additional Information:
Study ID Numbers: CDR0000257029; NCI-5663,PMH-PHL-009
Study Start Date:
Record last reviewed: November 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00045669
Other Stage 3 Salivary Gland Cancer Studies:
1. Trastuzumab in Treating Patients With Advanced Salivary Gland Cancer
2. Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
3. Gemcitabine in Treating Patients With Recurrent or Metastatic Adenoid Cystic Cancer of the Head and Neck
Related Studies:
Other stage 3 salivary gland cancer Clinical Trials
Other Indiana Clinical Trials
Other South Bend Clinical Trials
Imatinib Mesylate in Treating Patients With Salivary Gland Cancer
|
|
|
|
|
|
|
|
